Abarceo Pharma, ett bolag i pre-klinisk fas som utvecklar en plattform för behandling av mitrokondiska sjukdomar med initialt fokus på typ-2 diabetes (T2D).
We are happy to announce LSI Epsilons sixth investment VoxlBio. VoxlBio are empowering discoveries through advanced genetic spatial analysis. Tools that change how we can understand and diagnose komplex diseases as cancer. We are looking forward to the journey...
Video on Youtube: here. Spotify: here.
LSI portfolio company Acorai, a Swedish developer and manufacturer of innovative devices for heart failure management, announced the closing of a $4.5M investment from the EIC Fund, Taiwan Medical University, and private investors. The capital will be used to complete...